Neurodevelopmental Outcomes in Very Low Birth Weight Infants Using Aminophylline for the Treatment of Apnea

Tey, Shu-Leei; Lee, Wei-Te; Lee, Pei-Lun; Lu, Cheng‐Chang; Chen, Hsiu-Lin

doi:10.1016/j.pedneo.2015.03.013

Cited by 14 publications

(12 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Aminophylline is used more commonly outside the USA, and one study from Korea comparing 52 infants treated with aminophylline compared with 52 patients not given aminophylline found higher rates of BPD in treated patients but no changes in neurodevelopmental outcomes 25. However, as this was a retrospective study there may have been additional factors that were different between these two groups.…”

Section: Treatmentmentioning

confidence: 85%

Treatment options for apnoea of prematurity

Morton

Smith

2016

Arch Dis Child Fetal Neonatal Ed

View full text Add to dashboard Cite

Apnoea of prematurity (AOP) affects almost all infants born at <28 weeks gestation or with birth weight <1000 g. When untreated, AOP may be associated with negative outcomes. Because of these negative outcomes, effective treatment for AOP is an important part of optimising care of preterm infants. Standard treatment usually involves xanthine therapy and respiratory support. Cutting-edge work with stochastic vibrotactile stimulation and new pharmaceutical agents continues to expand therapeutic options. In this article, we review the pathophysiology of AOP, associated conditions and treatment options.

show abstract

Section: Treatmentmentioning

confidence: 85%

Treatment options for apnoea of prematurity

Morton

Smith

2016

Arch Dis Child Fetal Neonatal Ed

View full text Add to dashboard Cite

show abstract

“…[15,16] Aminophylline continues to be used in preterm infants in developing countries due to either lack of availability or cost of caffeine. [17][18][19] …”

Section: Discussionmentioning

confidence: 99%

Aminophylline-associated hyponatremia in a premature infant

et al. 2017

View full text Add to dashboard Cite

Hyponatremia is common in preterm infants. The causes are usually related to the inability of the premature kidneys to excrete a given water load, excessive sodium losses, or inadequate sodium intake. Here, we present a case of severe hyponatremia in an extreme preterm infant, associated with the use of aminophylline. Aminophylline was administered intravenously on day 1 for the treatment of apnea of prematurity. On day 3, the patient developed hyponatremia which was not responsive to sodium replacement and fluid restriction. Due to concerns of aminophylline-induced hyponatremia, aminophylline was discontinued on day 6, and within 48 h of discontinuation, serum sodium normalized without the need for sodium supplementation. The purpose of the case report is to present a rare complication associated with aminophylline use and to shed light on potential deleterious effects associated with drug shortages.

show abstract

“…Caffeine demonstrated better enteral absorption, higher therapeutic ratio and longer half‐life; this allowed once‐daily administration with fewer plasma concentration fluctuations, greater penetration into the CNS without producing fluctuations in cerebral blood flow and fewer adverse effects than theophylline . Although several studies suggested aminophylline was a comparable, more easily available and cheaper alternative to caffeine, caffeine has become the drug of choice for AOP …”

Section: Respiratory Distress In the Neonatesmentioning

confidence: 99%

Phosphodiesterase inhibitors: Potential role in the respiratory distress of neonates

Mokrá

Mokrý

Matasová

2018

Pediatric Pulmonology

View full text Add to dashboard Cite

Phosphodiesterases (PDEs) are a superfamily of enzymes that catalyze the hydrolysis of phosphodiester bonds of 3',5' cyclic adenosine and guanosine monophosphate (cAMP and cGMP). PDEs control hydrolysis of cyclic nucleotides in many cells and tissues. Inhibition of PDEs by selective or nonselective PDE inhibitors represents an effective targeted strategy for the treatment of various diseases including respiratory disorders. Recent data have demonstrated that PDE inhibitors can also be of benefit in respiratory distress in neonates. This article outlines the pharmacological properties of nonselective and selective PDE inhibitors and provides up-to-date information regarding their use in experimental models of neonatal respiratory distress as well as in clinical studies.

show abstract

Neurodevelopmental Outcomes in Very Low Birth Weight Infants Using Aminophylline for the Treatment of Apnea

Cited by 14 publications

References 27 publications

Treatment options for apnoea of prematurity

Treatment options for apnoea of prematurity

Aminophylline-associated hyponatremia in a premature infant

Phosphodiesterase inhibitors: Potential role in the respiratory distress of neonates

Contact Info

Product

Resources

About